Complications of invasive mycoses in organ transplant recipients

References

• Silveira EP, Husain S, Kwak EJ, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transplant Infect Dis. 2007;9:22–27.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12(3):220–229.
   PubMed Web of Science ®Google Scholar
• Menzin J, Meyers JL, Friedman M, et al. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2011;39(4):e15–e20.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Marriott DJ, Chen SC, et al. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transpl Infect Dis. 2009;11(2):122–127.
   PubMed Web of Science ®Google Scholar
• Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation. 2003;75:2023–2029.
   PubMed Web of Science ®Google Scholar
• Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycology. 2007;45:305–320.
   PubMed Web of Science ®Google Scholar
• Fortun JP, Martin-Davila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002;8:1065–1070.
   PubMed Web of Science ®Google Scholar
• Lehmann JB, Smallwood GA, Lesniak LA, et al. Review of patient outcomes of aspergillus prophylaxis with voriconazole after lung transplantation. J Heart Lung Transpl. 2005;24(Suppl 1):S169.
   Web of Science ®Google Scholar
• Fortun J, Montejo M, Martin-Davila P, et al. Prospective, multicentre study of caspofungin for prophylaxis in high-risk liver transplantation. European Council for Clinical Microbiology and Infectious Diseases, Munich, Germany, April 2007. 2007.
   Google Scholar
• Paya CV. Fungal infections in solid-organ transplanation. Clin Infect Dis. 1993;16:677–688.
   PubMed Web of Science ®Google Scholar
• Schaenman JM, Rosso F, Austin JM, et al. Trends in invasive disease due to Candida species following heart and lung transplantation. Transpl Infect Dis. 2009;11(2):112–121.
   PubMed Web of Science ®Google Scholar
• Wahidi MM, Willner DA, Snyder LD, et al. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest. 2009;135(2):484–491.
   PubMed Web of Science ®Google Scholar
• Hadjiliadis DH, Howell DN, Davis RD, et al. Anastomotic infections in lung transplant recipients. Ann Transplant. 2000;3:13–19.
   Google Scholar
• Singh N, Huprikar S, Burdette SD, et al. Donor-derived fungal infections in organ transplant recipients: guidelines of the American society of transplantation, infectious diseases community of practice. Am J Transplant. 2012;12(9):2414–2428.
   PubMed Web of Science ®Google Scholar
• Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS disease transmission advisory committee. Am J Transplant. 2009;9(8):1929–1935.
   PubMed Web of Science ®Google Scholar
• Matignon M, Botterel F, Audard V, et al. Outcome of renal transplantation in eight patients with Candida sp. contamination of preservation fluid. Am Transplant. 2008;8(3):697–700.
   PubMed Web of Science ®Google Scholar
• Albano L, Bretagne S, Mamzer-Bruneel MF, et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis. 2009;48(2):194–202.
   PubMed Web of Science ®Google Scholar
• Gomez CA, Singh N. Donor-derived filamentous fungal infections in solid organ transplant recipients. Curr Opin Infect Dis. 2013;26(4):309–316.
   PubMed Web of Science ®Google Scholar
• Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol. 2005;43(Suppl 1):S49–S58.
   PubMed Web of Science ®Google Scholar
• Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation. 1997;64:716–720.
   PubMed Web of Science ®Google Scholar
• Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis. 2003;36:46–52.
   PubMed Web of Science ®Google Scholar
• Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study. Clin Infect Dis. 2005;41:52–59.
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65(5):453–464.
   PubMed Web of Science ®Google Scholar
• Gonwa TA, McBride MA, Anderson K, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant. 2006;6:2651–2659.
   PubMed Web of Science ®Google Scholar
• Saliba F, Delvart V, Ichai P, et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. Clin Transplant. 2013;27(4):E454–E461.
   PubMed Web of Science ®Google Scholar
• Lichtenstern C, Hochreiter M, Zehnter VD, et al. Pretransplant model for end stage liver disease score predicts posttransplant incidence of fungal infections after liver transplantation. Mycoses. 2013;56(3):350–357.
   PubMed Web of Science ®Google Scholar
• Higgins R, McNeil K, Dennis C, et al. Airway stenoses after lung transplantation: management with expanding metal stents. J Heart Lung Transplant. 1994;13:774–778.
   PubMed Web of Science ®Google Scholar
• Westney GE, Kesten S, De Hoyos A, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996;61:915–919.
   PubMed Web of Science ®Google Scholar
• Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation. 2001;71(2):242–246.
   PubMed Web of Science ®Google Scholar
• Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 1998;26:753–755.
   PubMed Web of Science ®Google Scholar
• Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112:1160–1164.
   PubMed Web of Science ®Google Scholar
• Nunley DR, Ohori NP, Grgurich WF, et al. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest. 1998;114:1321–1329.
   PubMed Web of Science ®Google Scholar
• Helmi M, Love RB, Welter D, et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest. 2003;123(3):800–808.
   PubMed Web of Science ®Google Scholar
• Heimann SM, Cornely OA, Wisplinghoff H, et al. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole. Eur J Clin Microbiol Infect Dis. 2015;34(2):331–338.
   PubMed Web of Science ®Google Scholar
• Shoham S, Marr KA. Invasive fungal infections in solid organ transplant recipients. Future Microbiol. 2012;7(5):639–655.
   PubMed Web of Science ®Google Scholar
• Rentz A, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998;27:781–788.
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41(9):1232–1239.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Kollef MH, Arnold H, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis. 2010;10:150.
   PubMed Web of Science ®Google Scholar
• Ha YE, Peck KR, Joo EJ, et al. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother. 2012;56(7):3950–3956.
   PubMed Web of Science ®Google Scholar
• Arnold HM, Micek ST, Shorr AF, et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy. 2010;30(4):361–368.
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Kett DH, et al. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. Pharmacoeconomics. 2011;29(8):705–717.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Moet GJ, et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY antimicrobial surveillance program (2008-2009). Int J Antimicrob Agents. 2011;38(1):65–69.
   PubMed Web of Science ®Google Scholar
• Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008;32(Suppl 2):S87–91.
   PubMed Web of Science ®Google Scholar
• Moran C, Grussemeyer CA, Spalding JR, et al. Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control. 2010;38(1):78–80.
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;24:2472–2482.
   Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–e50.
   PubMed Web of Science ®Google Scholar
• Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5(1):26–34.
   PubMed Web of Science ®Google Scholar
• Tong KB, Lau CJ, Murtagh K, et al. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis. 2009;13(1):24–36.
   PubMed Web of Science ®Google Scholar
• Sun HY, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis. 2011;53(2):168–176.
   PubMed Web of Science ®Google Scholar
• Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis. 2007;7:395–401.
   PubMed Web of Science ®Google Scholar
• Lanternier F, Chandesris MO, Poire S, et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant. 2007;12:2826–2828.
   Web of Science ®Google Scholar
• Massarollo PC, Mies S, Abdala E, et al. Immunosuppression withdrawal for treatment of severe infections in liver transplantation. Transpl Proceed. 1998;4:1472–1474.
   Web of Science ®Google Scholar
• Antinori S, Corbellino M, Necchi A, et al. Immune reconstitution inflammatory syndrome associated with Aspergillus terreus pulmonary infection in an autologous stem cell transplant recipient. Transpl Infect Dis. 2010;12(1):64–68.
   PubMed Web of Science ®Google Scholar
• Miceli MH, Maertens J, Buvé K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer. 2007 Jul 1;110(1):112–120.
   PubMed Web of Science ®Google Scholar
• Todeschini G, Murari C, Bonesi R, et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest. 1999;29(5):453–457.
   PubMed Web of Science ®Google Scholar
• Singh N, Suarez JF, Avery R, et al. Immune reconstitution syndrome-like entity in lung transplant recipients with invasive aspergillosis. Transpl Immunol. 2013;29(1–4):109–113.
   PubMed Web of Science ®Google Scholar
• Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10(11):791–802.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19(10):1043–1049.
   PubMed Web of Science ®Google Scholar
• Shelburne SA 3rd, Darcourt J, White AC Jr., et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(7):1049–1052.
   PubMed Web of Science ®Google Scholar
• Cadena J, Thompson GR 3rd, Ho TT, et al. Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker adalimumab in cryptococcal pneumonia. Diagn Microbiol Infect Dis. 2009;64(3):327–330.
   PubMed Web of Science ®Google Scholar
• Crespo G, Cervera C, Michelena J, et al. Immune reconstitution syndrome after voriconazole treatment for cryptococcal meningitis in a liver transplant recipient. Liver Transpl. 2008;14(11):1671–1674.
   PubMed Web of Science ®Google Scholar
• Singh N, Lortholary O, Alexander BD, et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin Infect Dis. 2005;40(12):1756–1761.
   PubMed Web of Science ®Google Scholar
• Ingram PR, Howman R, Leahy MF, et al. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis. 2007;44(12):e115–e117.
   PubMed Web of Science ®Google Scholar
• Legrand F, Lecuit M, Dupont B, et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis. 2008;46(5):696–702.
   PubMed Web of Science ®Google Scholar
• Saint-Faust M, Boyer C, Gari-Toussaint M, et al. Adjuvant corticosteroid therapy in 2 children with hepatosplenic candidiasis-related IRIS. J Pediatr Hematol Oncol. 2009;31(10):794–796.
   PubMed Web of Science ®Google Scholar
• Airas L, Paivarinta M, Roytta M, et al. Central nervous system immune reconstitution inflammatory syndrome (IRIS) after hematopoietic SCT. Bone Marrow Transplant. 2010;45(3):593–596.
   PubMed Web of Science ®Google Scholar
• Jazwinski A, Naggie S, Perfect J. Immune reconstitution syndrome in a patient with disseminated histoplasmosis and steroid taper: maintaining the perfect balance. Mycoses. 2011;54(3):270–272.
   PubMed Web of Science ®Google Scholar
• Hage CA, Bowyer S, Tarvin SE, et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50(1):85–92.
   PubMed Web of Science ®Google Scholar
• Barry SM, Lipman MC, Deery AR, et al. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med. 2002;3(3):207–211.
   PubMedGoogle Scholar
• Godoy MC, Silva CI, Ellis J, et al. Organizing pneumonia as a manifestation of Pneumocystis jiroveci immune reconstitution syndrome in HIV-positive patients: report of 2 cases. J Thorac Imaging. 2008;23(1):39–43.
   PubMed Web of Science ®Google Scholar
• Jagannathan P, Davis E, Jacobson M, et al. Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: a cautionary case series. AIDS. 2009;23(13):1794–1796.
   PubMed Web of Science ®Google Scholar
• Mori S, Polatino S, Estrada YMRM. Pneumocystis-associated organizing pneumonia as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected individual with a normal CD4+ T-cell count following antiretroviral therapy. Int J STD AIDS. 2009;20(9):662–665.
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocomprised hosts: immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47:226–235.
   PubMed Web of Science ®Google Scholar
• Lewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Med Mycol. 2009;47(Suppl 1):S271–281.
   PubMed Web of Science ®Google Scholar
• Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother. 2005;55(2):214–222.
   PubMed Web of Science ®Google Scholar
• Mihu MR, Pattabhi R, Nosanchuk JD. The impact of antifungals on toll-like receptors. Front Microbiol. 2014;5:99.
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Roilides E, Paliogianni F, et al. Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of toll-like receptors. Antimicrob Agents Chemother. 2008;52(9):3301–3306.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14(12):2758–2764.
   PubMed Web of Science ®Google Scholar
• Sun HY, Alexander BD, Huprikar S, et al. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. Clin Infect Dis. 2015;60(1):36–44.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Malena M, et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transplant. 2006;12:850–858.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;48(5):503–535.
   PubMed Web of Science ®Google Scholar
• Practice ASTIDCo, Pappas PG, Silveira FP. Candida in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S173–S179.
   PubMed Web of Science ®Google Scholar
• Singh N, Wagener MM, Cacciarelli TV, et al. Antifungal management practices in liver transplant recipients. Am J Transplant. 2008;8:426–431.
   PubMed Web of Science ®Google Scholar
• Steinbach W, Singh N, Miller JL, et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob Agents Chemotherap. 2004;48:4922–4925.
   PubMed Web of Science ®Google Scholar
• Coilly A, Fougerou-Leurent C, de Ledinghen V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation - The CO23 ANRS CUPILT study. J Hepatol. 2016;65(4):711–718.
   Web of Science ®Google Scholar
• Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131:729–737.
   PubMed Web of Science ®Google Scholar
• Fortun J, Muriel A, Martin-Davila P, et al. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: a propensity score analysis. Liver Transpl. 2016;22(4):427–435.
   PubMed Web of Science ®Google Scholar
• Saliba F, Pascher A, Cointault O, et al. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. 2015;60(7):997–1006.
   PubMed Web of Science ®Google Scholar
• Laverdiere M, Bow EJ, Rotstein C, et al. Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol. 2014;25(6):327–343.
   PubMed Web of Science ®Google Scholar
• Drew RH, Dodds Ashley E, Benjamin DK Jr., et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation. 2004;77(2):232–237.
   PubMed Web of Science ®Google Scholar
• Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation. 2003;75:1571–1574.
   PubMed Web of Science ®Google Scholar
• Peghin M, Monforte V, Martin-Gomez MT, et al. 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation. Transpl Int. 2016;29(1):51–62.
   PubMed Web of Science ®Google Scholar
• Hamacher J, Spiliopoulos A, Kurt AM, et al. Pre-emptive therapy with azoles in lung transplant patients. Eur Respir J. 1999;13:180–186.
   PubMed Web of Science ®Google Scholar
• Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant. 2009;9(9):2085–2091.
   PubMed Web of Science ®Google Scholar
• Bhaskaran A, Mumtaz K, Husain S. Anti-Aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis. Curr Infect Dis Rep. 2013;15(6):514–525.
   PubMed Web of Science ®Google Scholar
• Husain S, Paterson DL, Studer SM, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;12:2765–2773.
   Google Scholar
• Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant. 2012;31(7):694–699.
   PubMed Web of Science ®Google Scholar
• Zwald FO, Spratt M, Lemos BD, et al. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol Surg. 2012;38(8):1369–1374.
   PubMed Web of Science ®Google Scholar
• Wang TF, Wang T, Altman R, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant. 2009;9(12):2845–2850.
   PubMed Web of Science ®Google Scholar
• Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. 2011;52(5):604–611.
   PubMed Web of Science ®Google Scholar
• Robinson CL, Chau C, Yerkovich ST, et al. Posaconazole in lung transplant recipients: use, tolerability, and efficacy. Transpl Infect Dis. 2016;18(2):302–308.
   PubMed Web of Science ®Google Scholar
• Thakuria L, Packwood K, Firouzi A, et al. A pharmacokinetic analysis of posaconazole oral suspension in the serum and alveolar compartment of lung transplant recipients. Int J Antimicrob Agents. 2016;47(1):69–76.
   PubMed Web of Science ®Google Scholar
• Brett J, Chong O, Graham GG, et al. Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients. Ther Drug Monit. 2013;35(1):133–136.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Manavathu EK. Molecular characterization of a voriconazole-resistant, posaconazole-susceptible Aspergillus fumigatus isolate in a lung transplant recipient in the United States. Antimicrob Agents Chemother. 2015;60(2):1129–1133.
   PubMed Web of Science ®Google Scholar
• Sayah DM, Schwartz BS, Kukreja J, et al. Scedosporium prolificans pericarditis and mycotic aortic aneurysm in a lung transplant recipient receiving voriconazole prophylaxis. Transpl Infect Dis. 2013;15(2):E70–E74.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Anil Kumar V, Sharma C, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33(6):919–926.
   PubMed Web of Science ®Google Scholar